Preprints available now:

1. Geraghty T, Obeidat AM, Ishihara S, Wood MJ, Li J, Lopes EBP, Scanzello CR, Griffin TM, Malfait AM, Miller RE. Age-associated changes in knee osteoarthritis, pain-related behaviors, and dorsal root ganglia immunophenotyping of male and female mice. bioRxiv 2022.07.07.499172; doi:

2. Obeidat AM, Wood MJ, Ishihara S, Li J, Wang L, Ren D, Bennett DA, Miller RJ, Malfait AM, Miller RE. Piezo2 expressing nociceptors mediate mechanical sensitization in experimental osteoarthritis. bioRxiv 2022.03.12.484097; doi:

For a full list of publications, see PubMed.

  1. Ishihara S, Obeidat AM, Wokosin DL, Ren D, Miller RJ, Malfait AM, Miller RE. The role of intra-articular neuronal CCR2 receptors in knee joint pain associated with experimental osteoarthritis in mice. Arthritis Research & Therapy. 2021;23:103. [Article]
  2. Geraghty T, Winter DR, Miller RJ, Miller RE, Malfait AM. Neuroimmune interactions and osteoarthritis pain: focus on macrophages. PAIN Reports. 2021;6(1):e892. [PubMed]
  3. Syx D, Miller RE, Obeidat AM, Tran PB, Vroman R, Malfait Z, Miller RJ, Malfait F, Malfait AM. Pain-related behaviors and abnormal cutaneous innervation in a murine model of classical Ehlers-Danlos syndrome. Pain. 2020;161(10):2274-83. [PubMed]
  4. Malfait AM, Miller RE, Block JA. Targeting neurotrophic factors: Novel approaches to musculoskeletal pain. Pharmacol Ther. 2020;211:107553. [PubMed]
  5. Malfait AM, Miller RE. Why we should study osteoarthritis pain in experimental models in both sexes. Osteoarthritis Cartilage. 2020;28(4):397-399. [PubMed]
  6. Miller RE, Tran PB, Ishihara S, Syx D, Ren D, Miller RJ, Valdes AM, Malfait AM. Microarray Analyses of the Dorsal Root Ganglia Support a Role for Innate Neuro-Immune Pathways in Persistent Pain in Experimental Osteoarthritis. Osteoarthritis Cartilage. 2020;28(5):581-592. [PubMed]
  7. Miller RJ, Malfait AM, Miller RE. The innate immune response as a mediator of osteoarthritis pain. Osteoarthritis Cartilage. 2020;28(5):562-571. [PubMed]
  8. Alles SRA, Malfait AM, Miller RJ. Chemo- and Optogenetic Strategies for the Elucidation of Pain Pathways. The Oxford Handbook of the Neurobiology of Pain. Online publication date Nov 2019. [OxfordHandbooks]
  9. Miller RE, Scanzello CR, Malfait AM. An emerging role for Toll-like receptors at the neuroimmune interface in osteoarthritis. Seminars in Immunopathology. 2019;41(5):583-594. [PubMed]
  10. Obeidat AM, Miller RE, Miller RJ, Malfait AM. The Nociceptive Innervation Of The Normal And Osteoarthritic Mouse Knee. Osteoarthritis Cartilage. 2019;27(11):1669-1679. [PubMed]
  11. Chua JR, Jamal S, Riad M, Castrejon I, Malfait AM, Block JA, Pincus T. Disease burden in osteoarthritis (OA) is similar to rheumatoid arthritis (RA) at initial rheumatology visit and significantly greater 6-months later. Arthritis Rheumatol. 2019;71(8):1276-1284. [PubMed]
  12. Miller RE, Ishihara S, Tran PB, Golub SB, Last K, Miller RJ, Fosang AJ, Malfait AM. An aggrecan fragment drives osteoarthritis pain through Toll-like receptor 2. JCI Insight. 2018;3(6):e95704. [PubMed]
  13. Miller RE, Kim YS, Tran PB, Ishihara S, Dong X, Miller RJ, Malfait AM. Visualization of Peripheral Neuron Sensitization in a Surgical Mouse Model of Osteoarthritis by In Vivo Calcium Imaging. Arthritis Rheumatol. 70:88. 2018. [PubMed]
  14. Miller RE, Block JA, Malfait AM. What is new in pain modification in osteoarthritis. Rheumatology. 57:iv99. 2018. [PubMed]
  15. Syx D, Tran PB, Miller RE, Malfait AM. Peripheral Mechanisms Contributing to Osteoarthritis Pain. Curr Rheum Rep. 20:9. 2018. [PubMed]
  16. Malfait AM, Pincus T. Pain in rheumatic diseases. Clin Exp Rheumatol. 35:1. 2017. [PubMed]
  17. Miller RE, Malfait AM, Block JA. Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain. Clin Exp Rheumatol. 35:85. 2017. [PubMed]
  18. Miller RE, Miller RJ. Is cannabis an effective treatment for joint pain? Clin Exp Rheumatol. 35:59. 2017. [PubMed]
  19. Malfait AM. Why we should study pain in animal models of rheumatic diseases. Clin Exp Rheumatol. 35:37. 2017. [PubMed]
  20. Sambamurthy N, Nguyen V, Smalley R, Xiao R, Hankenson K, Gan J, Miller RE, Malfait AM, Dodge GR, Scanzello CR. Chemokine receptor-7 (CCR7) deficiency leads to delayed development of joint damage and functional deficits in a murine model of osteoarthritis. J Orthop Res. In Press. 2017. [PubMed]
  21. Miller RE, Ishihara S, Bhattacharyya B, Delaney A, Menichella DM, Miller RJ, Malfait AM. Chemogenetic Inhibition of Pain Neurons in a Mouse Model of Osteoarthritis. Arthritis Rheumatol. 69:1429. 2017. [PubMed][Editorial]
  22. Miller RE and Malfait AM. Can we target CCR2 to treat osteoarthritis? The trick is in the timing! Osteoarthritis Cartilage. 25:799. 2017. [PubMed]
  23. Malfait AM and Miller RJ. Emerging Targets for the Management of Osteoarthritis Pain. Curr Osteoporos Rep. 14:260. 2016. [PubMed]
  24. Vincent T, Malfait AM. Time to be positive about negative data? Osteoarthritis Cartilage. 25:351. 2017. [PubMed]
  25. Miotla Zarebska J, Chanalaris A, Driscoll C, Burleigh A, Miller RE, Malfait AM, Stott B, Vincent TL. CCL2 and CCR2 regulate pain-related behaviour and early gene expression in post-traumatic murine osteoarthritis but contribute little to chondropathy. Osteoarthritis Cartilage. 25:406-412. 2017. [PubMed]
  26. Miller RE, Block JA, Malfait AM. Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models? Curr Opin Rheumatol. 29:110-118. 2017. [PubMed]
  27. Tran PB, Miller RE, Ishihara S, Miller RJ, Malfait AM. Spinal Microglial Activation in a Murine Surgical Model of Knee Osteoarthritis. Osteoarthritis Cartilage. 25:718-726. 2017. [PubMed][Editorial]
  28. Miller RE, Tran PB, Ishihara S, Larkin J, Malfait AM. Therapeutic effects of an anti-ADAMTS-5 antibody on joint damage and mechanical allodynia in a murine model of osteoarthritis. Osteoarthritis Cartilage. 24:299. 2016. [PubMed]
  29. Malfait AM. Osteoarthritis year in review 2015: biology. Osteoarthritis Cartilage. 24:21. 2016. [PubMed]
  30. Miller RE, Belmadani A, Ishihara S, Tran PB, Ren D, Miller RJ, Malfait AM. Damage-Associated Molecular Patterns Generated in Osteoarthritis Directly Excite Murine Nociceptive Neurons through Toll-like Receptor 4. Arthritis & Rheumatology. 67(11):2933-43. 2015. [PubMed]
  31. Miller RE, Tran PB, Obeidat AM, Raghu P, Ishihara S, Miller RJ, Malfait AM. The Role of Peripheral Nociceptive Neurons in the Pathophysiology of Osteoarthritis Pain. Current Osteoporosis Reports. 13(5):318-26. 2015. [PubMed]
  32. Malfait AM and Little CB. On the predictive utility of animal models of osteoarthritis. Arthritis Res Ther. 17:225. 2015. [PubMed]
  33. Chen S, Cao P, Dong N, Peng J, Zhang C, Wang H, Zhou T, Yang J, Zhang Y, Martelli EE, Naga Prasad SV, Miller RE, Malfait AM, Zhou Y, Wu Q. PCSK6-mediated corin activation is essential for normal blood pressure. Nature Medicine. 21(9):1048-53. 2015. [PubMed]
  34. Larkin J, Lohr TA, Elefante L, Shearin J, Matico R, Su JL, Xue Y, Liu F, Genell C, Miller RE, Tran PB, Malfait AM, Maier CC, Matheny CJ. Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification. Osteoarthritis Cartilage. 23(8):1254-66. 2015. [PubMed]
  35. Miller RE, Miller RJ, Malfait AM. Osteoarthritis joint pain: The cytokine connection. Cytokine. 70(2):185-93. 2014. [PubMed]
  36. Malfait AM, Schnitzer TJ. Towards a mechanism-based approach to pain management in osteoarthritis. Nat Rev Rheumatol. 9(11):654-664. 2013. [PubMed]
  37. Malfait AM, Little CB, McDougall JJ. A commentary on modelling osteoarthritis pain in small animals. Osteoarthritis Cartilage. 21(9):1316-1326. 2013. [PubMed]
  38. Miller RE, Lu Y, Tortorella MD, Malfait AM. Genetically Engineered Mouse Models Reveal the Importance of Proteases as Osteoarthritis Drug Targets. Curr Rheumatol Rep. 15(9):350. 2013. [PubMed]
  39. Miller RE, Tran PB, Das R, Ghoreishi-Haack N, Ren D, Miller RJ, Malfait AM. CCR2 chemokine receptor signaling mediates pain in experimental osteoarthritis. PNAS. 109(50):20602-7. 2012. [PubMed]
  40. Morgen M, Tung D, Boras B, Miller W, Malfait AM, Tortorella MD. Nanoparticles for Improved Local Retention after Intra-Articular Injection into the Knee Joint. Pharmaceutical Research. 30(1):257-68. 2013. [PubMed]
  41. Malfait AM, Seymour AB, Gao F, Tortorella MD, Le Graverand-Gastineau MPH, Wood LS, Doherty M, Doherty S, Zhang W, Arden NK, Vaughn FL, Leaverton PE, Spector TD, Hart DJ, Maciewicz RA, Muir KR, Das R, Sorge RE, Sotocinal SG, Schorscher-Petcu A, Valdes AM, Mogil JS. A role for PACE4 in osteoarthritis pain: evidence from human genetic association and null mutant phenotype. Annals of the Rheumatic Diseases. 71(6):1042-8. 2012. [PubMed]
  42. Nair A, Kanda V, Bush-Joseph C, Verma N, Chubinskaya S, Mikecz K, Glant TT, Malfait AM, Crow MK, Spear GT, Finnegan A, Scanzello CR. Synovial fluid from patients with early osteoarthritis modulates fibroblast-like synoviocyte responses to TLR-4 and TLR-2 ligands via soluble CD14. Arthritis Rheum. 64(7):2268-77. 2012. [PubMed]
  43. Malfait AM. Modelling pain in post-traumatic osteoarthritis of the knee. Pain. 153(2):257-8. 2012. [PubMed]
  44. Shieh HS, Tomasselli AG, Mathis KJ, Schnute ME, Woodard SS, Caspers N, Williams JM, Kiefer JR, Munie G, Wittwer A, Malfait AM, Tortorella MD. Structure analysis reveals the flexibility of the ADAMTS-5 active site. Protein Sci. 20(4):735-44. 2011. [PubMed]
  45. Malfait AM, Ritchie J, Gil AS, Austin JS, Hartke J, Qin W, Tortorella MD, Mogil JS. ADAMTS-5 deficient mice do not develop mechanical allodynia associated with osteoarthritis following medial meniscal destabilization. Osteoarthritis Cartilage. 18(4):572-80. 2010. [PubMed]
  46. Byun S, Tortorella MD, Malfait AM, Fok K, Frank EH, Grodzinsky AJ. Transport and equilibrium uptake of a peptide inhibitor of PACE4 into articular cartilage is dominated by electrostatic interactions. Arch Biochem Biophys. 499(1-2):32-9. 2010. [PubMed]
  47. Zack MD, Melton MA, Stock JL, Storer CE, Barve RA, Minnerly JC, Weiss DJ, Stejskal JA, Tortorella MD, Turk JR, Shevlin KM, Malfait AM. Reduced incidence and severity of experimental autoimmune arthritis in mice expressing catalytically inactive A disintegrin and metalloproteinase 8 (ADAM8). Clin Exp Immunol. 158(2):246-56. 2009. [PubMed]

[Back to Top]